- United States
- /
- Household Products
- /
- NasdaqGS:CENT
Market Cool On Central Garden & Pet Company's (NASDAQ:CENT) Earnings
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for feeling indifferent about Central Garden & Pet Company's (NASDAQ:CENT) P/E ratio of 20.3x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/E.
While the market has experienced earnings growth lately, Central Garden & Pet's earnings have gone into reverse gear, which is not great. It might be that many expect the dour earnings performance to strengthen positively, which has kept the P/E from falling. If not, then existing shareholders may be a little nervous about the viability of the share price.
Check out our latest analysis for Central Garden & Pet
Is There Some Growth For Central Garden & Pet?
There's an inherent assumption that a company should be matching the market for P/E ratios like Central Garden & Pet's to be considered reasonable.
Retrospectively, the last year delivered a frustrating 16% decrease to the company's bottom line. As a result, earnings from three years ago have also fallen 31% overall. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.
Looking ahead now, EPS is anticipated to climb by 17% per annum during the coming three years according to the five analysts following the company. That's shaping up to be materially higher than the 11% per year growth forecast for the broader market.
With this information, we find it interesting that Central Garden & Pet is trading at a fairly similar P/E to the market. Apparently some shareholders are skeptical of the forecasts and have been accepting lower selling prices.
What We Can Learn From Central Garden & Pet's P/E?
While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
Our examination of Central Garden & Pet's analyst forecasts revealed that its superior earnings outlook isn't contributing to its P/E as much as we would have predicted. When we see a strong earnings outlook with faster-than-market growth, we assume potential risks are what might be placing pressure on the P/E ratio. It appears some are indeed anticipating earnings instability, because these conditions should normally provide a boost to the share price.
Plus, you should also learn about these 2 warning signs we've spotted with Central Garden & Pet.
It's important to make sure you look for a great company, not just the first idea you come across. So take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:CENT
Central Garden & Pet
Produces and distributes various products for the lawn and garden, and pet supplies markets in the United States.
Flawless balance sheet and undervalued.
Similar Companies
Market Insights
Weekly Picks

Looking to be second time lucky with a game-changing new product

Second order memory play likely to double in a year

Intuitive Machines: To The Moon and Beyond!
AppLovin’s AI Engine Is Printing Profit
Recently Updated Narratives

Gaining Ground on Nvidia

Significant headwinds will temper expectations for FY2027

Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
NVIDIA will see a profit margin surge of 55% in the next 5 years
